세계의 이상혈색소증 치료 시장 보고서(2025년)

Hemoglobinopathies Treatment Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이상혈색소증 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 9.9%의 성장률(CAGR)을 기록하며 144억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 맞춤형 의료의 중요성, 희귀질환에 대한 규제 지원, 산전 선별검사 프로그램 시행, 임신 중 헤모글로빈 이상 질환을 조기에 발견할 수 있는 유전 상담 서비스, 질병 교정 치료의 채택 확대 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 신규 약물 치료, 세포 치료, 정밀치료법의 발전, 진단 도구의 개선 등이 있습니다.

유전적 유전의 유병률 증가는 향후 이상혈색소증 치료 시장의 성장을 견인할 것으로 예상됩니다. 유전은 유성 또는 무성 여부에 관계없이 생식 시 DNA를 통해 부모로부터 자녀에게 특성이 전달되는 것을 포함합니다. 유전자 연구와 기술 개발은 이상혈색소증을 포함한 다양한 질병에서 유전적 요인의 중요성을 부각시키고, 표적 치료, 맞춤 의료, 의약품 개발 및 진단의 개선으로 이어지고 있습니다. 예를 들어, 영국에 기반을 둔 등록 자선단체인 진 피플스(Gene People)에 따르면, 25명 중 1명이 유전성 질환을 앓고 있으며, 매년 약 3만 명의 영유아가 새롭게 진단을 받고 있는 것으로 추정됩니다. 이에 따라 유전적 유병률의 증가는 이상혈색소증 치료 시장 확대의 원동력이 되고 있습니다.

이상혈색소증 치료 시장의 주요 업체들은 이러한 유전적 질환을 앓고 있는 환자들에게 잠재적인 치료법을 제공하기 위해 세포 기반 유전자 치료제를 적극적으로 개발하고 있습니다. 이상혈색소증에 대한 세포 기반 유전자 치료는 근본적인 유전적 결함을 교정하고, 장기적 또는 치료 효과를 가져올 수 있으며, 증상과 합병증을 완화하고, 환자의 치료 옵션을 발전시킬 것으로 기대됩니다. 예를 들어, 2023년 12월 미국 생명공학 기업 버텍스 파마슈티컬스(Vertex Pharmaceuticals Inc.)는 겸상 적혈구증(SCD) 및 수혈 의존성 베타 지중해빈혈 치료제로 캐스제비를 발표했습니다. 캐스제비는 CRISPR/Cas9 기술을 이용해 환자의 조혈모세포를 편집하여 태아 헤모글로빈 생산을 증가시켜 적혈구의 겸상 적혈구증을 예방하는 세포 기반 유전자 치료제입니다. 이 치료법은 환자의 줄기세포를 채취, 편집, 재주입하는 일회성 치료 과정으로 이루어집니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신종 코로나바이러스 감염증, 그리고 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 이상혈색소증 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 이상혈색소증 치료 시장 : 성장률 분석
• 세계의 이상혈색소증 치료 시장 실적 : 규모와 성장, 2019-2024
• 세계의 이상혈색소증 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 이상혈색소증 치료 전체 시장(TAM)

제6장 시장 세분화

• 세계의 이상혈색소증 치료 시장 : 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 줄기세포 치료
• 수혈
• 세계의 이상혈색소증 치료 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 지중해빈혈
• 병적 세포 빈혈
• 세계의 이상혈색소증 치료 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 온라인 프로바이더
• 드럭스토어와 소매 약국
• 세계의 이상혈색소증 치료 시장, 줄기세포 치료 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 조혈모세포 이식(HSCT)
• 이상헤모글로빈증에 대한 유전자 치료
• 자가 줄기세포 치료
• 동종 줄기세포 이식
• 유전자 편집 기술(CRISPR-Cas9)
• 제대혈 줄기세포 치료
• 골수 이식
• 세계의 이상혈색소증 치료 시장, 수혈 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 정기적인 수혈(빈혈의 경우)
• 교환 수혈
• 수혈 후 철킬레이트 요법
• 적혈구 수혈
• 하플로타입 일치 수혈
• 백혈구 제거 수혈
• 중증의 경우 긴급 수혈

제7장 지역별·국가별 분석

• 세계의 이상혈색소증 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 이상혈색소증 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 이상혈색소증 치료 시장 : 경쟁 구도
• 이상혈색소증 치료 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업과 혁신적 기업

• Vertex Pharmaceuticals Incorporated
• Pharmacosmos A/S
• Alnylam Pharmaceuticals
• Global Blood Therapeutics Inc.
• Acceleron Pharma Inc.
• Sangamo Therapeutics Inc.
• Gamida Cell Ltd.
• Beam Therapeutics
• Intellia Therapeutics
• Adaptimmune Therapeutics
• Orchard Therapeutics plc
• Fresenius SE & Co. KGaA
• Editas Medicine
• Agios Pharmaceuticals Inc.
• Emmaus Life Sciences Inc.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 이상혈색소증 치료 시장 2029 : 새로운 기회를 제공하는 국가
• 이상혈색소증 치료 시장 2029 : 새로운 기회를 제공하는 부문
• 이상혈색소증 치료 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Hemoglobinopathies treatment encompasses the management and care offered to individuals affected by genetic disorders involving abnormal or mutated hemoglobin molecules, such as sickle cell disease and thalassemia. The objective of treating hemoglobinopathies is to alleviate symptoms, prevent complications, and potentially offer curative options to enhance patient outcomes and quality of life.

The primary types of treatment for hemoglobinopathies include stem cell therapy and blood transfusion. Stem cell therapy utilizes stem cells to address or prevent a disease or condition, particularly in cases of thalassemia and sickle cell anemia. These treatments can be accessed through various channels, including hospital pharmacies, online providers, drug stores, and retail pharmacies.

The hemoglobinopathies treatment market research report is one of a series of new reports from The Business Research Company that provides hemoglobinopathies treatment market statistics, including hemoglobinopathies treatment industry global market size, regional shares, competitors with a hemoglobinopathies treatment market share, detailed hemoglobinopathies treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobinopathies treatment industry. This hemoglobinopathies treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemoglobinopathies treatment market size has grown rapidly in recent years. It will grow from $9.01 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to scientific discoveries, medical advances, patient advocacy, public health awareness, international collaboration and research consortia.

The hemoglobinopathies treatment market size is expected to see strong growth in the next few years. It will grow to $14.49 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing emphasis on personalized medicine, regulatory support for rare diseases, implementation of prenatal screening programs, genetic counselling services enabled early detection of hemoglobinopathies during pregnancy and expanded adoption of disease-modifying therapies. Major trends in the forecast period include novel drug therapies, cellular therapies, advancements in precision therapeutics, improved diagnostic tools.

The increasing prevalence of genetic inheritance is expected to drive the growth of the hemoglobinopathies treatment market in the future. Genetic inheritance involves the transmission of characteristics from parents to offspring through DNA during reproduction, whether sexual or asexual. Advances in genetic research and technology have underscored the significance of genetic factors in various diseases, including hemoglobinopathies, leading to improved targeted therapies, personalized medicine, drug development, and diagnosis. For example, according to Gene People, a UK-based registered charity, it is estimated that 1 in every 25 children has a genetic disorder, with approximately 30,000 babies and children newly diagnosed each year. Consequently, the increasing prevalence of genetic inheritance is a driving force behind the expansion of the hemoglobinopathies treatment market.

Key players in the hemoglobinopathies treatment market are actively developing cell-based gene therapies to offer potentially curative treatments for patients with these genetic conditions. Cell-based gene therapies for hemoglobinopathies hold promise in correcting underlying genetic defects, potentially providing long-term or curative effects, alleviating symptoms and complications, and advancing treatment options for affected individuals. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biotech company, introduced Casgevy for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia. Casgevy is a cell-based gene therapy employing CRISPR/Cas9 technology to edit patients' hematopoietic stem cells, enhancing the production of fetal hemoglobin to prevent red blood cell sickling. The therapy involves a one-time treatment process comprising the collection, editing, and reinfusion of the patient's stem cells.

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired Global Blood Therapeutics Inc. for $5.4 billion, aiming to enhance its pipeline and portfolio for rare hematology, particularly in sickle cell disease (SCD), and to leverage its experience to better serve the underserved SCD patient community worldwide. Global Blood Therapeutics Inc., a US-based biopharmaceutical company dedicated to discovering, developing, and delivering drugs for hemoglobinopathies treatment, specializes in sickle cell disease.

Major companies operating in the hemoglobinopathies treatment market are Pfizer Inc., Sanofi S.A., Novartis AG, Bristol Myers Squibb, Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Pharmacosmos A/S, Alnylam Pharmaceuticals, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Gamida Cell Ltd., Beam Therapeutics, Intellia Therapeutics, Adaptimmune Therapeutics, Orchard Therapeutics plc, Fresenius SE & Co. KGaA, Editas Medicine, Agios Pharmaceuticals Inc., Emmaus Life Sciences Inc., Bluebird Bio Inc, CRISPR Therapeutics AG, Bioverativ Inc., Celgene Corporation, EMI Holding Inc.

North America was the largest region in the hemoglobinopathies treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemoglobinopathies treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hemoglobinopathies treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hemoglobinopathies treatment market consists of revenues earned by entities by providing services such as medication, blood transfusions, bone marrow transplantation, gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemoglobinopathies treatment market also includes sales of iron chelation therapy and hydroxyurea. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemoglobinopathies Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemoglobinopathies treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemoglobinopathies treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hemoglobinopathies treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Stem Cell Therapy; Blood Transfusion
• 2) By Application: Thalassemia; Sick Cell Anemia
• 3) By Distribution Channel: Hospital Pharmacy; Online Providers; Drug Stores And Retail Pharmacy
• Subsegments:
• 1) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (Hsct); Gene Therapy For Hemoglobinopathies; Autologous Stem Cell Therapy; Allogeneic Stem Cell Transplantation; Gene Editing Techniques ( Crispr-cas9); Umbilical Cord Blood Stem Cell Therapy; Bone Marrow Transplantation
• 2) By Blood Transfusion: Regular Blood Transfusion (For Anemia); Exchange Blood Transfusion; Iron Chelation Therapy Post-Transfusion; Red Blood Cell Transfusions; Haploidentical Blood Transfusions; Leukoreduced Blood Transfusion; Emergency Blood Transfusion In Severe Cases
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Novartis AG; Bristol Myers Squibb; Gilead Sciences Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hemoglobinopathies Treatment Market Characteristics

3. Hemoglobinopathies Treatment Market Trends And Strategies

4. Hemoglobinopathies Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Hemoglobinopathies Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hemoglobinopathies Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hemoglobinopathies Treatment Market Growth Rate Analysis
• 5.4. Global Hemoglobinopathies Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hemoglobinopathies Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hemoglobinopathies Treatment Total Addressable Market (TAM)

6. Hemoglobinopathies Treatment Market Segmentation

• 6.1. Global Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stem Cell Therapy
• Blood Transfusion
• 6.2. Global Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thalassemia
• Sick Cell Anemia
• 6.3. Global Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Providers
• Drug Stores And Retail Pharmacy
• 6.4. Global Hemoglobinopathies Treatment Market, Sub-Segmentation Of Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Transplantation (HSCT)
• Gene Therapy For Hemoglobinopathies
• Autologous Stem Cell Therapy
• Allogeneic Stem Cell Transplantation
• Gene Editing Techniques (CRISPR-Cas9)
• Umbilical Cord Blood Stem Cell Therapy
• Bone Marrow Transplantation
• 6.5. Global Hemoglobinopathies Treatment Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regular Blood Transfusion (For Anemia)
• Exchange Blood Transfusion
• Iron Chelation Therapy Post-Transfusion
• Red Blood Cell Transfusions
• Haploidentical Blood Transfusions
• Leukoreduced Blood Transfusion
• Emergency Blood Transfusion In Severe Cases

7. Hemoglobinopathies Treatment Market Regional And Country Analysis

• 7.1. Global Hemoglobinopathies Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hemoglobinopathies Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hemoglobinopathies Treatment Market

• 8.1. Asia-Pacific Hemoglobinopathies Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hemoglobinopathies Treatment Market

• 9.1. China Hemoglobinopathies Treatment Market Overview
• 9.2. China Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hemoglobinopathies Treatment Market

• 10.1. India Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hemoglobinopathies Treatment Market

• 11.1. Japan Hemoglobinopathies Treatment Market Overview
• 11.2. Japan Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hemoglobinopathies Treatment Market

• 12.1. Australia Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hemoglobinopathies Treatment Market

• 13.1. Indonesia Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hemoglobinopathies Treatment Market

• 14.1. South Korea Hemoglobinopathies Treatment Market Overview
• 14.2. South Korea Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hemoglobinopathies Treatment Market

• 15.1. Western Europe Hemoglobinopathies Treatment Market Overview
• 15.2. Western Europe Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hemoglobinopathies Treatment Market

• 16.1. UK Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hemoglobinopathies Treatment Market

• 17.1. Germany Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hemoglobinopathies Treatment Market

• 18.1. France Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hemoglobinopathies Treatment Market

• 19.1. Italy Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hemoglobinopathies Treatment Market

• 20.1. Spain Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hemoglobinopathies Treatment Market

• 21.1. Eastern Europe Hemoglobinopathies Treatment Market Overview
• 21.2. Eastern Europe Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hemoglobinopathies Treatment Market

• 22.1. Russia Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hemoglobinopathies Treatment Market

• 23.1. North America Hemoglobinopathies Treatment Market Overview
• 23.2. North America Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hemoglobinopathies Treatment Market

• 24.1. USA Hemoglobinopathies Treatment Market Overview
• 24.2. USA Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hemoglobinopathies Treatment Market

• 25.1. Canada Hemoglobinopathies Treatment Market Overview
• 25.2. Canada Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hemoglobinopathies Treatment Market

• 26.1. South America Hemoglobinopathies Treatment Market Overview
• 26.2. South America Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hemoglobinopathies Treatment Market

• 27.1. Brazil Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hemoglobinopathies Treatment Market

• 28.1. Middle East Hemoglobinopathies Treatment Market Overview
• 28.2. Middle East Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hemoglobinopathies Treatment Market

• 29.1. Africa Hemoglobinopathies Treatment Market Overview
• 29.2. Africa Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hemoglobinopathies Treatment Market Competitive Landscape And Company Profiles

• 30.1. Hemoglobinopathies Treatment Market Competitive Landscape
• 30.2. Hemoglobinopathies Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hemoglobinopathies Treatment Market Other Major And Innovative Companies

• 31.1. Vertex Pharmaceuticals Incorporated
• 31.2. Pharmacosmos A/S
• 31.3. Alnylam Pharmaceuticals
• 31.4. Global Blood Therapeutics Inc.
• 31.5. Acceleron Pharma Inc.
• 31.6. Sangamo Therapeutics Inc.
• 31.7. Gamida Cell Ltd.
• 31.8. Beam Therapeutics
• 31.9. Intellia Therapeutics
• 31.10. Adaptimmune Therapeutics
• 31.11. Orchard Therapeutics plc
• 31.12. Fresenius SE & Co. KGaA
• 31.13. Editas Medicine
• 31.14. Agios Pharmaceuticals Inc.
• 31.15. Emmaus Life Sciences Inc.

32. Global Hemoglobinopathies Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hemoglobinopathies Treatment Market

34. Recent Developments In The Hemoglobinopathies Treatment Market

35. Hemoglobinopathies Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Hemoglobinopathies Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hemoglobinopathies Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hemoglobinopathies Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료